Meecham Jones D J, Paul E A, Jones P W, Wedzicha J A
Respiratory Care Unit, London Chest Hospital, United Kingdom.
Am J Respir Crit Care Med. 1995 Aug;152(2):538-44. doi: 10.1164/ajrccm.152.2.7633704.
Non-invasive ventilation has been used in chronic respiratory failure due to chronic obstructive pulmonary disease (COPD), but the effect of the addition of nasal positive-pressure ventilation to long-term oxygen therapy (LTOT) has not been determined. We report a randomized crossover study of the effect of the combination of nasal pressure support ventilation (NPSV) and domiciliary LTOT as compared with LTOT alone in stable hypercapnic COPD. Fourteen patients were studied, with values (mean +/- SD) of Pao2 of 45.3 +/- 5.7 mm Hg, PaCO2 of 55.8 +/- 3.6 mm Hg, and FEV1 of 0.86 +/- 0.32 L. A 4 wk run-in period (on usual therapy) was followed by consecutive 3-mo periods of: (1) oxygen therapy alone, and (2) oxygen plus NPSV in randomized order. Assessments were made during run-in and at the end of each study period. There were significant improvements in daytime arterial PaO2 and PaCO2, total sleep time, sleep efficiency, and overnight PaCO2 following 3 mo of oxygen plus NPSV as compared with run-in and oxygen alone. Quality of life with oxygen plus NPSV was significantly better than with oxygen alone. The degree of improvement in daytime PaCO2 was correlated with the improvement in mean overnight PaCO2. Nasal positive-pressure ventilation may be a useful addition to LTOT in stable hypercapnic COPD.
无创通气已用于慢性阻塞性肺疾病(COPD)所致的慢性呼吸衰竭,但长期氧疗(LTOT)联合鼻正压通气的效果尚未确定。我们报告了一项随机交叉研究,比较了鼻压力支持通气(NPSV)与家庭LTOT联合应用与单纯LTOT对稳定期高碳酸血症COPD患者的影响。研究了14例患者,其动脉血氧分压(Pao2)为45.3±5.7 mmHg,动脉血二氧化碳分压(PaCO2)为55.8±3.6 mmHg,第一秒用力呼气容积(FEV1)为0.86±0.32 L。在4周的导入期(采用常规治疗)后,依次进行连续3个月的以下治疗:(1)单纯氧疗,(2)氧疗加NPSV,顺序随机。在导入期和每个研究期结束时进行评估。与导入期和单纯氧疗相比,氧疗加NPSV治疗3个月后,白天动脉血氧分压和二氧化碳分压、总睡眠时间、睡眠效率及夜间二氧化碳分压均有显著改善。氧疗加NPSV时的生活质量明显优于单纯氧疗。白天二氧化碳分压的改善程度与夜间平均二氧化碳分压的改善相关。在稳定期高碳酸血症COPD患者中,鼻正压通气可能是LTOT的有益补充。